As leaders in Real World Evidence Generation and experts in understanding patients and HCPs, we are here to partner with you and support with
- Broad and deep disease area understanding
- Evidence needs and gaps, incl. publications development
- Insights feeding into your strategy
The Dermatology DSPs portfolio includes well established conditions (covering Adult and Pediatric patients) alongside emerging indications where real world data is limited.
The Atopic Dermatitis programme (wave 4 in 2026) captures the evolving treatment landscape dynamics, with opportunities to add enrichment samples of new entrant products such as lebrikizumab and nemolizumab. We have a range of additional in-house data covering other AD patient cohorts to address more tailored research questions, including advanced therapy discontinuers, patients with moderate-to-severe disease treated with topical therapies, and APP-managed patients.
There is in house Psoriasis, Hidradenitis Suppurativa and Alopecia Areata data collected in the past year, incl. enrichment samples of patients receiving advanced therapies.
We are currently running wave II of the Vitiligo DSP, incl. a sample of patients receiving ruxolitinib and expanding the geographical coverage.
Other dermatology conditions in development (data collection in 2026) include bullous pemphigoid, lichen simplex chronicus and chronic urticaria (CSU and CIndU).
Feedback on data collection materials design is welcome for all programmes that are not fielded yet!
Dermatology Conditions Disease Specific Programmes (DSP) Portfolio
The DSPs answer a broad range of objectives, exploring in depth patient sub-groups:
- Understanding patient populations and defining disease severity: clinical outcomes & PROMs (incl. mental health), disease control and what matters to patients most
- Improving patient experience across their disease journey
- Real world effectiveness of newly launched products, adherence and persistence – head to head comparative analysis
- Treatment utilisation patterns, incl. sequencing and reasons for switching
- Patients’ quality of life, clinical and economical disease burden
- Patient equity and treatment access disparities
Topics we have published recently on include:
- Patient journey: diagnosis, management, classification - Click here to view example
- Treatment landscape and real-world drug use and effectiveness - Click here to view example
- Alignment of patient-physician perspectives - Click here to view example
- Patient unmet needs - Click here to view example
- Economic burden of illness - Click here to view example
We are attending AAD and EADV this year and welcome meeting you in person there!
In the meantime, let’s arrange an online introductory call.